Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COCOON: Enhanced Dermatologic Management in EGFR-Mutated NSCLC Treated With Amivantamab + Lazertinib
NCT06120140Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2024
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) at 12 weeks. Started Feb 2024; status: active, not recruiting.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06120140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120140.